Karyopharm Therapeutics | KPTI - Процентные расходы





Процентные расходы Изменить Дата
AbbVie USD 645M 69M 2026-03
Abbott USD 299M 231M 2026-06
Amgen USD 95.64B 94.98B 2026-06
AstraZeneca USD 340M 144M 2026-06
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
GlaxoSmithKline GBP 121M 46M 2026-06
Incyte USD 582K 13K 2026-06
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.55M 66K 2026-03
MacroGenics USD 4.89M 1.55M 2026-03
Merck USD 525M 46M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Novartis USD 462M 119M 2026-06
Novartis USD 281M 8M 2025-09
Pfizer USD 667M 4M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Takeda JPY 63.85B 20.2B 2026-06
Tectonic Therapeutic USD 246.58M 246.56M 2026-03
TG Therapeutics USD 16.57M 8.91M 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Xencor USD 7.35M 2.65M 2026-06